MedTrace Logo

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

NCT03679780 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-06-11

No results posted yet for this study

Summary

The goal of the study is to examine the possible mechanisms of impaired cutaneous microvascular function through local heating along with administration of vasoconstrictors.

Conditions

Interventions

DRUG

BQ-788

This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min

DRUG

BQ-123

This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min

DRUG

L-Arginine

A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min

DRUG

NG Nitro L Arginine Methyl Ester

L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min

DRUG

Sodium Nitroprusside

SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min

DRUG

Lactated Ringer's

Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min

Sponsors & Collaborators

  • The University of Texas at Arlington

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2023-07-26
Completion
2023-07-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03679780 on ClinicalTrials.gov